anti ythdc1 primary antibody (Proteintech)
Structured Review

Anti Ythdc1 Primary Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 98 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti ythdc1 primary antibody/product/Proteintech
Average 96 stars, based on 98 article reviews
Images
1) Product Images from "Loss of YTHDC1 m 6 A reading function promotes invasiveness in urothelial carcinoma of the bladder"
Article Title: Loss of YTHDC1 m 6 A reading function promotes invasiveness in urothelial carcinoma of the bladder
Journal: Experimental & Molecular Medicine
doi: 10.1038/s12276-024-01377-x
Figure Legend Snippet: a Kaplan‒Meier ten-year overall survival analysis of patients with different levels of YTHDC1 using data from the Mannheim University Hospital cohort. Statistical significance was assessed by the log-rank test. b Comparison of YTHDC1 mRNA expression between NMIBC ( n = 18) and MIBC ( n = 80) patients in the Mannheim University Hospital cohort. ** p -value < 0.01, Mann‒Whitney U test. c YTHDC1 mRNA expression levels in NMIBC compared with MIBC samples from the published Fudan cohort and UROMOL cohorts. *** p -value < 0.001, ** p -value < 0.01, Mann‒Whitney U test. d Representative H&E staining (upper panel) and IHC (lower panel) results showing YTHDC1 expression across different stages of bladder cancer. Scale bar = 100 μm. Quantitative analyses of the YTHDC1 IHC assays are shown in the right panels, which were performed via the IRS method and compared between paratumoral and tumor tissues (above), as well as between NMIBC and MIBC tissues (below). *** p -value < 0.001, ** p -value < 0.01, Mann‒Whitney U test. e Pearson correlation analyses between YTHDC1 expression (Log 2 (normalized counts +1)) and canonical EMT markers (Log 2 (normalized counts +1)) in the TCGA-BLCA dataset, with p -values and correlation coefficients (r) provided. f Relative YTHDC1 expression (Log 2 (normalized counts +1)) in the p-EMT high ( n = 206) and p-EMT low ( n = 206) groups in the TCGA-BLCA dataset. *** p value < 0.001.
Techniques Used: Comparison, Expressing, Staining
Figure Legend Snippet: a Western blot showing YTHDC1 depletion (upper panel) and knockdown (lower panel) in UROtsa cells. b Viability of UROtsa cells upon YTHDC1 depletion (upper panel) or knockdown (lower panel), as analyzed by the CellTiter-Glo assay. The experiments were performed in biological and technical triplicates. p -value < 0.0001, two-way analysis of variance (ANOVA). c Colony formation assays in UROtsa YTHDC1 control (Ctrl) and YTHDC1-depleted (KO) cells (above) or UROtsa control (Scr3) and YTHDC1-knockdown (Sh3) cells (below). Representative images are displayed on the left, while the quantification and statistics of three independent replicates using the ColonyArea algorithm in ImageJ are shown on the right. *** p -value < 0.001, * p -value < 0.05; unpaired two-sided t test. d Apoptotic cell levels in UROtsa cells depleted of YTHDC1 compared with those in control (above) and sh3 vs. Scr3 cells (below), as measured by Caspase-3/7-Glo assays with biological and technical triplicates. ** p -value < 0.01, unpaired two-sided t test . e Transwell migration assays for YTHDC1 Ctrl and YTHDC1-depleted (upper panel) or Scr3 and Sh3 (lower panel) UROtsa cells. Representative images were taken using a 20x objective lens and are displayed on the left, while the quantification and statistics of the relative number of migrated cells are shown on the right. ** p -value < 0.01, * p -value < 0.05, unpaired two-sided t test. f Transwell invasion assays for YTHDC1 Ctrl and YTHDC1-depleted (above), or Scr3 and Sh3 (below) UROtsa cells. Representative images were taken using a 20x objective lens and are displayed on the left, while the quantification and statistics of relative cell invasion are shown on the right. ** p -value < 0.01, * p -value < 0.05, unpaired two-sided t test. All Transwell experiments were performed with 3 biological replicates. g Colony formation assays in BLCA cell lines (UM-UC-3, T24, RT112, and RT4) with the YTHDC1 empty vector (EV) or YTHDC1-overexpressing (OE) cells. Representative images of UM-UC-3 cells are displayed on the left, while quantification and statistics of all BLCA cell lines from three independent replicates using the ColonyArea algorithm in ImageJ are shown on the right. *** p -value < 0.001, unpaired two-sided t test. h Apoptosis levels in BLCA cell lines with YTHDC1 overexpression compared with those with empty vector, as measured by Caspase-3/7-Glo assays with biological and technical triplicates. *** p -value < 0.001, unpaired two-sided t test. i Transwell invasion assays in BLCA cell lines with YTHDC1 EV and YTHDC1 OE. The representative images shown are the invasion assays in UM-UC-3 cell lines, which were taken with a 20x objective lens and are displayed on the left. Representative images of UM-UC-3 cells (left, 20x objective) and quantification of all of the cell lines (right) are shown. *** p -value < 0.001, ** p -value < 0.01, unpaired two-sided t test. j Quantification of migration assays in BLCA cell lines with empty vector or YTHDC1 overexpression. *** p -value < 0.001, ** p -value < 0.01, unpaired two-sided t test.
Techniques Used: Western Blot, Knockdown, Glo Assay, Control, Migration, Plasmid Preparation, Over Expression
Figure Legend Snippet: a Schematic illustration of our inhibitor approach to disrupt the interaction of YTHDC1 with m 6 A-modified RNAs, with the molecular structure of the YTHDC1 inhibitor depicted on the right. b Western blot showing the protein levels of YTHDC1 and METTL3 in wild-type UROtsa cells after treatment with the YTHDC1 inhibitor. The quantification results obtained via ImageJ are shown on the right. * p -value < 0.05; ns: not significant; unpaired two-sided t -test. c Transwell migration assays of UROtsa cells treated with DMSO (control) or the YTHDC1 inhibitor. Representative images were taken using a 20x objective lens and are displayed on the left, while the quantification and statistics of relative cell migration in three independent replicates are shown on the right. *** p -value < 0.001, unpaired two-sided t test. d Transwell invasion assays for UROtsa cells treated with DMSO (control) or the YTHDC1 inhibitor. Representative images were taken using a 20x objective lens and are displayed on the left, while the quantification and statistics of relative cell invasion in three independent replicates are shown on the right. * p -value < 0.05, unpaired two-sided t test.
Techniques Used: Modification, Western Blot, Migration, Control
Figure Legend Snippet: a Volcano plot illustrating the significantly altered transcripts in YTHDC1-depleted cells compared with Ctrl cells. Downregulated genes are shown in blue, whereas upregulated genes are shown in red. q < 0.05. b GSEA plots demonstrating the specific dysregulation of gene sets associated with EMT and cell adhesion in YTHDC1-depleted cells compared with control UROtsa cells. The plots display the normalized enriched score (NES) and corresponding p -values. c GO analysis of the DEGs between YTHDC1-depleted and control UROtsa cells, highlighting the enrichment of metastasis-related processes. d Venn diagram showing the overlap between the differentially expressed transcripts ( | Log 2 Foldchange (FC)| > 1.5, q < 0.05) upon YTHDC1 depletion in UROtsa cells and those known to be m 6 A modified, as recently determined by GLORI mapping . e Heatmaps presenting the expression levels of overlapping transcripts displayed in ( d ), specifically focusing on the terms related to metastasis from the GO analysis. f Transcripts in ( e ) exhibiting the highest Pearson correlation with YTHDC1 expression in TCGA-BLCA samples, with p -values and correlation efficiencies (r) shown in the plots.
Techniques Used: Control, Modification, Expressing
Figure Legend Snippet: a Representative Western blot showing YTHDC1 protein abundance in DMSO- and STM2457-treated wild-type UROtsa cells. IgG was used as an IP control. b Read counts (upper panel) from YTHDC1 RIP-seq data in the DMSO group, demonstrating enriched YTHDC1 binding across all transcripts. Blue line: YTHDC1 pulldown; red line: input signal. Heatmap (lower panel) showing enrichment of YTHDC1-bound transcripts in the 5’ to 3’ direction. Each row corresponds to a transcript bound by YTHDC1, where the intensity of the color reflects the enrichment level, with the scale bar shown on the right. c Pie charts displaying the distribution of YTHDC1 RIP-seq peaks in the DMSO and STM2457 groups (q < 0.01). d Venn diagram indicating the number of YTHDC1 binding targets in the DMSO and STM2457 treatment groups. p -value < 0.05. e Representative genome tracks depicting an example gene, STEAP1, bound by YTHDC1, with lower peaks in the STM2457 treatment group than in the DMSO group. f Heatmaps illustrating enriched YTHDC1 binding (normalized against the input control) in the DMSO and STM2457 treatment groups for all high-confidence YTHDC1-bound transcripts (determined by Diffbind, log 2 fold change < −1, p -value < 0.05). g Upper row: enriched motifs in YTHDC1-bound sequences identified by RIP-seq in the DMSO group ( p -value = 1e-35); lower row: enriched motifs in YTHDC1-bound sequences identified by RIP-seq in the high-confidence group ( p -value = 1e-22). h Venn diagram showing the intersection among high-confidence YTHDC1-bound transcripts, m 6 A-modified transcripts, and differentially expressed transcripts in YTHDC1-depleted cells ( | log 2 fold change | > 1.5, q -value < 0.05). The intersecting genes are listed in the middle, and representative peaks (signal intensity) are shown in the right panel to demonstrate the overlap between m 6 A peaks (GLORI ) and YTHDC1 binding peaks (RIP-seq).
Techniques Used: Western Blot, Quantitative Proteomics, Control, Binding Assay, Modification
Figure Legend Snippet: a Left panel: Pearson correlation analysis between YTHDC1 expression (Log 2 (normalized counts +1)) and SMAD6 (Log 2 (normalized counts +1)) in the TCGA-BLCA dataset, with p values and correlation coefficients (r) provided. Right panel: Ten-year overall survival analysis of SMAD6 in the TCGA-BLCA dataset. Log-rank test, p -value = 0.0001. b Comparison of SMAD6 expression in NMIBC and MIBC using data from the Fudan and UROMOL cohorts. *** p -value < 0.001, Mann‒Whitney U test. c Representative images of SMAD6 mRNA (yellow) and YTHDC1 protein (magenta) detected in paratumoral (upper row) and tumoral (lower row) FFPE tissues, respectively. The white arrows indicate SMAD6 -YTHDC1 colocalization. Scale bar = 10 μM. d Left panel: Colocalization detection results using Big-FISH of the abovementioned paratumoral and tumoral tissues. Scale bar = 10 μM. Right panel: Quantification of the percentage of colocalized SMAD6 foci. * p -value < 0.05, paired Student’s t test. e Relative luciferase activity in control and YTHDC1-depleted UROtsa cells transfected with wild-type or m 6 A-mutant SMAD6 5’UTR constructs. Three independent experiments were performed. *** p -value < 0.001, ns: not significant. f Time course qPCR analysis of SMAD6 mRNA expression in UROtsa cells following transfection with nontargeting control siRNA (siNC) or SMAD6 -targeting siRNA (siSMAD6). The experiments were performed with 3 biological replicates. *** p -value < 0.001, ** p -value < 0.01, * p -value < 0.05. g Quantification of Transwell invasion assays of UROtsa cells transfected with siNC and siSMAD6 after 24 h. Three biological replicates, ** p -value < 0.01. h Quantification of Transwell invasion assays of UROtsa Ctrl and YTHDC1-depleted cells transduced with empty vector (EV) and SMAD6 overexpression (OE). *** p -value < 0.001, ** p -value < 0.01, ns: not significant. One-way analysis of variance (ANOVA) followed by Tukey’s post hoc test was used.
Techniques Used: Expressing, Comparison, Luciferase, Activity Assay, Control, Transfection, Mutagenesis, Construct, Transduction, Plasmid Preparation, Over Expression
